# How Much Does Compounded Semaglutide Cost? What Drives the Number

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-14 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/what-drives-compounded-glp1-prices

> Compounded GLP-1 prices are quoted in ways that hide what you will be charged. This is the structure of the bill, and where on this site the dated numbers live.

## Key points

- No price appears in this article on purpose. Dated figures live on the price tracker and the ranked boards, where they can be re-verified.
- Seven mechanisms separate an advertised figure from a standing charge, including a "monthly" price billed every four weeks, which is thirteen charges a year rather than twelve.
- GLP-1 dosing is built to climb (both approved semaglutide labels hold the opening four weeks at 0.25 mg weekly), so a starting-strength price covers the shortest part of treatment.
- The FTC settled charges that a telehealth weight-loss operator advertised a membership price without adequately disclosing that the drug, the lab work and the consultation were billed separately.

This article does not tell you what compounded semaglutide or tirzepatide costs, and that is deliberate. Sellers change figures weekly, so any number written into a sentence here would be wrong before you read it. What does not change is the *shape* of the bill: the handful of ways a headline figure turns out not to be the amount you keep paying. Learn those, then get the current numbers from our [live price tracker](https://glpwatchdog.org/price-tracker), where each one carries the date we captured it.

> **Where the numbers live.** Dated figures per seller are on the [price tracker](https://glpwatchdog.org/price-tracker). Ranked boards are at [/best/compounded-semaglutide](https://glpwatchdog.org/best/compounded-semaglutide) and [/best/cheapest-semaglutide](https://glpwatchdog.org/best/cheapest-semaglutide). If a figure there is older than you are comfortable with, the seller's own checkout is the authority, and we want to hear about any disagreement.

## Seven ways an advertised figure is not the standing one

None of these is exotic, and most are legal. Each is arithmetic that happens somewhere other than the headline.

*How a quoted figure and a recurring charge come apart*

| The mechanism | What it means for the amount you actually pay |
| --- | --- |
| **An introductory rate** | The figure applies to the first month or the first order only. The renewal is a different number, and it is usually disclosed further down the page than the headline is. |
| **A membership fee** | The advertised amount buys access to the service. The medication is billed separately, and sometimes the consultation and the lab work are too. The FTC has brought an action over exactly this omission.[1][2] |
| **A prepaid term, divided** | You are quoted a per-month figure derived from a multi-month block you pay for upfront. Nobody is billed that per-month amount, and leaving early may not refund the unused part. |
| **A four-week cycle called a month** | A calendar year holds thirteen four-week periods, not twelve. Billed that way, a figure presented as monthly produces one extra charge every year, and the per-calendar-month cost is higher than the number implies. |
| **A per-vial figure** | A vial is a quantity of drug, not a unit of time. How long one lasts depends on your dose, so a per-vial figure shown next to the word month is a claim about your dose as much as about the price. |
| **A package total, divided** | A bundle covering several months, divided by its length. Same trap as the prepaid term, and it also hides what happens if you stop partway. |
| **A starting-dose price** | The figure covers the lowest strength. Where a program prices by strength (and in our own capture work many do), the number climbs with each step of the ladder, and GLP-1 dosing is built to climb. This is the mechanism that matters most on this drug class, and it gets its own section below. |

Several of these patterns are easy to find among the sellers we review. [Brello Health](https://glpwatchdog.org/reviews/brello-health) sells three-month plans that renew every 11 weeks, so its billing cycle and the word month do not line up. [Longevity Meds](https://glpwatchdog.org/reviews/longevity-meds) sets a mandatory three-month term in its payment policy and charges a fee to leave early, while its FAQ says the opposite. [CoraDoc](https://glpwatchdog.org/reviews/coradoc) works the other way around: its programs are paid once up front, and nothing renews. [Morph Health & Wellness](https://glpwatchdog.org/reviews/morph-health-wellness) sells its GLP-1/GIP package plans on terms of two to seven months, billed on the first of each month, and its FAQ says that once you opt into a package you agree to its duration.

## The dose ladder is not an accident, and neither is the price ladder

GLP-1 dosing starts low on purpose and rises on a schedule. Both approved semaglutide labels hold the opening four weeks at a 0.25 mg weekly dose; Wegovy injection then titrates every four weeks toward a usual maintenance dosage of 2.4 mg weekly, with a further step to 7.2 mg now allowed for some patients, and Ozempic steps up to a maintenance dosage of 0.5 mg, 1 mg or 2 mg, with 2 mg once weekly stated as the maximum recommended.[6][7] Compounded programs dose against that same clinical pattern of escalation.

So a price attached to a starting strength is a price for the part of treatment you spend the least time in. Ask what the figure becomes at each rung, and get the answer in writing.

Some sellers take the price ladder out of the bill entirely. [Basal Health](https://glpwatchdog.org/reviews/basal-health), [Lttl](https://glpwatchdog.org/reviews/lttl) and [KERNX Health](https://glpwatchdog.org/reviews/kernx-health) each charge one monthly price whatever the dose, while [Boston Medical Group](https://glpwatchdog.org/reviews/boston-medical-group) says in its FAQ that the monthly cost climbs with the dose. [Lemonaid Health](https://glpwatchdog.org/reviews/lemonaid-health) is a useful warning about reading the word flat: its fee holds steady across doses, but that fee is a membership, and the medication is charged on top. [Primma Wellness](https://glpwatchdog.org/reviews/primma-wellness) sells its one-month semaglutide and tirzepatide plans per order, at the same price at every dose.

> **Your dose is a clinical decision, not a budgeting one.** If a price step is the reason you are thinking about staying at a lower strength, or moving up faster, that is a conversation for your prescriber. FDA has received adverse event reports that may be related to compounded GLP-1 doses beyond the approved labeling, including titration that moved too fast.[5]

Prepaid bundles can carry their own ladder. [Fifty 410](https://glpwatchdog.org/reviews/fifty-410) charges one monthly price for tirzepatide at every dose, but its three-month tirzepatide programs are priced by dose level and paid in full up front.

## What the FTC has already said about this pattern

In July 2025 the Federal Trade Commission announced a settlement with the operators of a telehealth weight-loss company over how its programs were sold. The allegation at the center of it is the second mechanism in the table above: memberships advertised at a monthly price without adequately disclosing that the price did not cover the GLP-1 drug itself, the lab work needed to establish eligibility, or the consultation required to get a prescription.[2]

The complaint went further into the terms. The FTC alleged the programs carried a required one-year commitment with early termination fees that was not adequately disclosed, that cancellation and refund requests went unresolved because the company had not staffed to handle them, and that it did not obtain informed consent before charging people.[2] The proposed order bars misrepresenting the cost of telehealth services, including what that cost covers and the timing or manner of any charge, and requires refund and cancellation terms to be disclosed clearly before a consumer is asked to pay.[2] The final order was approved in December 2025.[1]

> **That case names one company, and only that company.** Southern Health Solutions, Inc. is the respondent; no seller in our register is a party to it, connected to it, or implied by it here. We cite it only because a federal regulator has described the mechanism on the record. Linking an enforcement action to a business takes a matching domain and registered entity.

## What legitimately differs between sellers

Not every gap between two quotes is a trick. Three real differences move the number, and it helps to know which one you are looking at before deciding a seller is expensive.

### The dose

Strength is the difference most likely to explain an honest gap. Two programs quoting different figures may simply be quoting different rungs of the ladder. A comparison only means something at the same dose, which is why our boards record the strength alongside each figure.

### What is inside the price

The consultation, follow-up visits, the lab panel, shipping, and the syringes and needles are each sometimes included and sometimes billed on their own. A quote that covers all of them is not comparable to one that covers the drug alone, and the difference is frequently larger than the gap between the two headline figures.

The two ends of that spectrum are easy to find. [Omzo](https://glpwatchdog.org/reviews/omzo) folds the medication and delivery into its single fee. [Medi-Weightloss](https://glpwatchdog.org/reviews/medi-weightloss) starts self-pay patients with a separately paid first visit that covers the assessment and the labs. [Thrivelab](https://glpwatchdog.org/reviews/thrivelab) posts its compounded semaglutide prices but charges for the first 40-minute telehealth appointment on its own, in cash or as a deposit when insurance is billed.

### 503A or 503B

A traditional pharmacy compounding under section 503A prepares a drug on receipt of a prescription for an individual patient. An outsourcing facility registered under section 503B operates under current good manufacturing practice requirements, is inspected by FDA on a risk-based schedule, and has to report adverse events.[3] Those are different cost structures, and they also carry different amounts of public evidence. Neither is FDA-approved: the agency does not review any compounded drug for safety, effectiveness or quality before it reaches a patient.[3] Which facility made your vial is a question with an answer, and our [pharmacy register](https://glpwatchdog.org/pharmacies) is where we keep those answers.

## One more variable, and it is legal rather than commercial

The compounded market's cheapest years ran on a shortage. FDA set the end of its enforcement discretion for compounded semaglutide at April 22, 2025 for state-licensed pharmacies and May 22, 2025 for outsourcing facilities, and as of its April 1, 2026 update neither semaglutide nor tirzepatide appears on the 503B bulks list or on the drug shortage list.[4] On April 30, 2026 the agency went further and proposed excluding semaglutide, tirzepatide and liraglutide from that bulks list.[8] The comment period closed July 30, 2026, and no final decision had been issued by October 17, 2026. A seller still offering these at scale should be able to say what it is relying on, and that is a fair question to ask alongside the price. We set out the rule in [which GLP-1s can be compounded](https://glpwatchdog.org/research/which-glp1-can-be-compounded) and the reader's options in [what to do when a compounded program ends](https://glpwatchdog.org/research/compounded-glp1-going-away-what-to-do).

A quote well below everything else in the market is worth pausing on for the same reason. FDA lists medicine offered at deep discounts, or at prices that look too good to be true, among its telehealth warning signs.[5] When we capture an unusually low figure, we treat it as a likely error on our side until we can reproduce it.

## Ask these before you pay

1. **Is the figure I am seeing the renewal figure?** If not, what is the renewal figure, in writing?
2. **How often will my card be charged, and on what cycle?** Every four weeks and once a calendar month are not the same commitment.
3. **Does this cover the medication itself?** Ask separately about the consultation, follow-ups, lab work, shipping and injection supplies.
4. **What am I committing to?** Minimum term, early termination fee, and what happens to money already paid if I stop.
5. **How do I cancel, and how long does it take?** A regulator has already brought a case where the answer to that was the problem.[2]
6. **What does this cost at the next dose, and the one after?** Get the whole ladder, not the rung you start on.[6]
7. **Which pharmacy compounds it, 503A or 503B?** The answer sets the manufacturing standard behind your vial.[3]
8. **What is the concentration, and how many doses is one vial at my strength?** That converts a per-vial figure into something you can compare.

If a program will not put those answers in writing before payment, that is information about the program. Take the answers you do get and check them against the dated figures on our [price tracker](https://glpwatchdog.org/price-tracker) and the [compounded semaglutide board](https://glpwatchdog.org/best/compounded-semaglutide). Sellers whose price says no membership is charged, or adds up as one all-in figure, are on the [no membership fee board](https://glpwatchdog.org/best/glp1-no-membership-fee). [Collective](https://glpwatchdog.org/reviews/collective)’s $59 monthly price for compounded semaglutide, by contrast, does not include the $199 annual membership it requires.

## Frequently asked questions

### How much does compounded semaglutide cost?

We do not answer that in article prose, on purpose. Seller pricing moves week to week, so a figure written into a sentence is wrong within a month and cannot be re-checked at scale. Every figure we publish sits on the price tracker or a ranked board with the date we captured it and the source it came from. Read this page for the structure, then read the tracker for the number.

### Why is compounded tirzepatide priced differently from compounded semaglutide?

They are different molecules at different strengths, often made by different compounding facilities, so the price of one is not a fair benchmark for the other. The same seven mechanisms apply to both: check the cycle, the renewal figure, what the price includes and what happens as the dose escalates.

### Does the price go up as my dose increases?

Often it does. Where a program prices by strength, the figure moves with the ladder, and GLP-1 dosing is built to escalate. Both approved semaglutide labels hold the opening four weeks at a 0.25 mg weekly dose, then step up from there. Ask a program for its figure at each strength before you start, not after.

### Is a very low advertised price a warning sign?

It is a reason to look harder. FDA lists deep discounts, or prices that seem too good to be true, among the telehealth warning signs it publishes for consumers. In our own work an unusually low figure is treated as a probable capture error until it is reproduced, and it is wrong more often than it is a real find.

### Is a membership fee the same as the cost of the medication?

Not necessarily, and that gap is what the FTC's 2025 action against a telehealth weight-loss operator was about. A membership can buy access to the service while the drug, the consultation and the lab work are billed separately. Ask which of those the advertised figure covers before you enter a card.

## References

1. U.S. Federal Trade Commission NextMed — Southern Health Solutions, Inc., also d/b/a Next Medical and NextMed (case page). FTC Cases and Proceedings. 2025. https://www.ftc.gov/legal-library/browse/cases-proceedings/nextmed
2. U.S. Federal Trade Commission FTC Takes Action Against Telemedicine Firm NextMed Over Charges It Used Misleading Prices, Fake Reviews, and Deceptive Weight Loss Claims to Sell GLP-1 Weight-Loss Programs. FTC Press Releases, July 14, 2025. 2025. https://www.ftc.gov/news-events/news/press-releases/2025/07/ftc-takes-action-against-telemedicine-firm-nextmed-over-charges-it-used-misleading-prices-fake
3. U.S. Food and Drug Administration Human Drug Compounding Laws. FDA Human Drug Compounding. 2024. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
4. U.S. Food and Drug Administration FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA Drug Alerts and Statements. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
5. U.S. Food and Drug Administration FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA Drug Alerts and Statements. 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
6. Novo Nordisk Pharmaceutical Industries, LP WEGOVY (semaglutide) injection and tablets — prescribing information, section 2 Dosage and Administration. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
7. Novo Nordisk Pharmaceutical Industries, LP OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information, section 2 Dosage and Administration. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
8. U.S. Food and Drug Administration FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. FDA Press Announcements, April 30, 2026. 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list

---

Cite as: GLP Watchdog, Nora Bissett, "How Much Does Compounded Semaglutide Cost? What Drives the Number", published 2026-08-14, updated 2026-11-02. https://glpwatchdog.org/research/what-drives-compounded-glp1-prices

Canonical HTML page: https://glpwatchdog.org/research/what-drives-compounded-glp1-prices

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.